The drug is decades old, and its intranasal option was first approved in 2015. The committee members said their greenlight votes were based on access barriers, the thousands of Americans who die every year from opioids and the low risk of errors.
The drugmaker Emergent BioSolutions filed the nonprescription application, according to the committee’s briefing document.
“It’s a huge public health benefit and it’s way overdue,” one panelist said.
The FDA is scheduled to make the final vote by March 29.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
